Ionis Pharmaceuticals and AstraZeneca failed a heart drug trial, leading to stock declines and market commentary.
4 reports, 4 independent
Updated Aug 6
Gone quiet
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ionis Pharmaceuticals and AstraZeneca failed a heart drug trial, leading to stock declines and market commentary.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ionis Pharmaceuticals
American pharmaceutical company
-
AstraZeneca
British-Swedish pharmaceutical company
Related events
- Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.
- Chinese pharmaceutical companies are investing heavily in novel technologies while AstraZeneca confirms its Cambridge headquarters and CEO.
- AstraZeneca is facing market pressure following a clinical trial failure, leading to a decline in its stock value.
- Joint drug trial success boosts Amgen stock.
- AstraZeneca discontinued the eVOLVE-Lung02 trial on August 18, 2026.